Latest Health News
QurAlis ANQUR Trial Shows Promise for ALS Treatment
QurAlis announced interim data from the Phase 1/2 ANQUR trial of QRL-201, demonstrating effects on disease progression, restoration of STATHMIN-2 expression, and slowing ALSFRS-R scores in sporadic ALS patients. Subgroup analysis confirmed statistically significant clinical efficacy and neurofilament biomarker changes.
Experts hail it as a promising early-stage result for precision medicine in ALS.
Stanford Develops Universal Nasal Spray Vaccine
Stanford Medicine unveiled a nasal spray vaccine that protects against viruses like COVID-19 and flu, bacterial pneumonia, and allergens by boosting lung innate immunity. In mice, it reduced viral loads 700-fold and enabled rapid adaptive responses within days.
The vaccine sustains protection for months without targeting specific pathogens.
Norway Study Links Hospital Sewage to AMR Spread
A Norwegian study reveals hospital sewage as a key vector for spreading antimicrobial resistance (AMR), contributing to over 35,000 EU deaths yearly. It underscores the need for One Health approaches, including the EU's 10-year OHAMR Partnership launched in 2025.
AMR remains a top EU health threat.
NIH Fogarty Lists Key Global Health Funding Opportunities
Fogarty International Center highlighted funding for global health research, including the Montrone-Seigel Prize and AFREhealth Conference abstracts due February 28. Opportunities cover administrative supplements, foreign components, and non-NIH grants for resilient Africa health systems.
Events focus on AI ethics, suicide prevention, and mpox lessons.
Cardinal Health Report: Biosimilars Drive $56B Savings
Cardinal Health's 2026 Biosimilars Report notes $56 billion in U.S. savings since 2015, with oncology biosimilars reaching 81% market share. Providers show strong confidence, expecting 25 new approvals in immunology, oncology, and retina.
It emphasizes access to high-quality therapies.
UNMC Secures $3.8M in Medical Research Grants
UNMC College of Medicine received over $3.8 million in new funding, including grants for autoimmune hepatitis, fear neurophysiology, and heart failure devices. Industry contracts cover VTE studies, cancer therapies, bronchiectasis drugs, and RSV vaccines in transplants.
Pediatric CSF biomarkers also funded.
FDA Framework Accelerates Ultra-Rare Disease Therapies
The FDA launched a framework to speed development of individualized therapies for ultra-rare diseases on February 23. It aims to enable faster access to precision treatments for patients with extremely low prevalence conditions.
This supports next-generation personalized medicine.
New Drug Delivery Platform for Genetic Medicines
University of Nottingham scientists created a self-assembling nanoscale platform for delivering RNA-based genetic medicines like vaccines and cancer treatments. Published in Advanced Materials, it offers safe, efficient, adaptable delivery.
It could accelerate gene-silencing drugs and next-gen therapies.
New Bone Marrow Model Advances Drug Discovery
Oxford researchers developed a scalable bone marrow model as a platform for next-generation drug discovery. It supports cross-cutting research with pump-priming awards.
This innovation enhances testing for blood-related diseases and therapies.
WHO Event on Frontiers in MCM R&D
WHO hosts 'Frontiers in MCM R&D' on February 26, exploring immunology, genomics, and synthetic biology for re-imagining medical countermeasures. It highlights convergence of breakthroughs in data science and manufacturing.
Aims to address global health threats innovatively.
AFREhealth Conference Calls for Abstracts on Resilient Africa
The 9th AFREhealth Conference seeks abstracts on strengthening health education, research, and service delivery for a resilient Africa; deadline February 28. Nominations open for Montrone-Seigel Prize honoring young biomedical investigators.
Part of broader NIH global health updates.